Company Filing History:
1 out of 1,835 
1 out of 132 
1 out of 73 
Years Active: 2022
Title: The Innovative Contributions of Chantal Boulanger-Robert
Introduction
Chantal Boulanger-Robert, an accomplished inventor based in Paris, France, has made significant strides in the medical field, particularly in the early prediction of hepatocellular carcinoma (HCC) in patients suffering from cirrhosis. Her groundbreaking research has contributed to the understanding of microvesicles' role in disease prediction, showcasing her expertise and dedication to advancing medical science.
Latest Patents
Chantal holds a noteworthy patent titled "Methods and kits for predicting the risk of having or developing hepatocellular carcinoma in patients suffering from cirrhosis." This innovative method involves measuring plasma levels of various sub-populations of microvesicles, including endothelial, leukocyte, platelet, and hepatocyte types, in blood samples from patients with cirrhosis. The study involved 125 patients, 36 of whom had been diagnosed with HCC at the time of inclusion. Her findings indicated that the levels of endothelial-derived microvesicles (specifically CD62E+) could effectively predict the occurrence of HCC in these patients, representing a significant advancement in risk assessment methodologies.
Career Highlights
Chantal Boulanger-Robert has developed her career primarily within esteemed institutions. She has worked at Inserm (Institut National de la Santé et de la Recherche Médicale), a leading French biomedical research institution, and Université Paris Descartes, renowned for its contributions to medical and health sciences. Her dedication to research and innovation has positioned her as a key figure in her field.
Collaborations
Throughout her career, Chantal has collaborated with esteemed colleagues, including Pierre-Emmanuel Rautou, enhancing the depth and breadth of her research initiatives. These collaborations have been instrumental in advancing the understanding of diseases like HCC and have significantly contributed to her success as an inventor.
Conclusion
Chantal Boulanger-Robert exemplifies the spirit of innovation within the medical research community. Her patent on predicting hepatocellular carcinoma risk represents a crucial step forward in patient care for those suffering from cirrhosis. As she continues her work, her contributions are set to influence the landscape of medical diagnostics and improve patient outcomes worldwide.